Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor

Nutrition and Cancer

Volumn 43, Issue 2, 2002, Pages 187-192

  Chen, Jianmin ^a   Mark Stavro, P ^a   Thompson, Lilian U ^a  

^a UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR; ESTROGEN RECEPTOR; KI 67 ANTIGEN; LIGNAN; LINOLEIC ACID; LINSEED OIL; OMEGA 3 FATTY ACID; PHYTOESTROGEN; SOMATOMEDIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER INCIDENCE; CANCER INHIBITION; CONTROLLED STUDY; DIETARY INTAKE; DOWN REGULATION; FEMALE; GROWTH RATE; IMMUNOHISTOCHEMISTRY; LABELING INDEX; LINSEED; LUNG METASTASIS; LUNG WEIGHT; METASTASIS INHIBITION; MOUSE; NONHUMAN; NUDE MOUSE; PROTEIN EXPRESSION; RANDOMIZATION; TUMOR VOLUME;

ANIMALIA; MUS MUSCULUS;

EID: 0036966926     PISSN: 01635581     EISSN: None     Source Type: Journal    
DOI: 10.1207/S15327914NC432_9     Document Type: Article

References (37)

1. Greenlee RT, Murray T, Bolden S, and Wingo PA: Cancer statistics, 2000. CA Cancer J Clin 50, 7-33, 2000.
2. Thompson LU: Flaxseed, lignans, and cancer. In Flaxseed in Human Nutrition, Cunnane SC and Thompson LU (eds). Champaign, IL: AOCS Press, 1995, pp 219-236.
3. Thompson LU: Experimental studies on lignans and cancer. Baillieres Clin Endocrinol Metab 12, 691-705, 1998.
4. Rose DP and Connolly JM: ω-3 fatty acids as cancer chemopreventive agents. Pharmacol Ther 83, 217-244, 1999.
5. Ingram D, Sanders K, Kolybaba M, and Lopez D: Case-control study of phyto-oestrogens and breast cancer. Lancet 350, 990-994, 1997.
6. Pietinen P, Stumpf K, Mannisto S, Kataja V, Uusitupa M, et al.: Serum enterolactone and risk of breast cancer: a case-control study in eastern Finland. Cancer Epidemiol Biomarkers Prev 10, 339-344, 2001.
7. Serraino M and Thompson LU: The effect of flaxseed supplementation on the initiation and promotional stages on mammary tumorigenesis. Nutr Cancer 17, 153-159, 1992.
8. Thompson LU, Rickard SE, Orcheson LJ, and Seidl MM: Flaxseed and its lignan and oil components reduce mammary tumor growth at a late stage of carcinogenesis. Carcinogeneisis 17, 1373-1376, 1996.
9. Thompson LU, Seidl MM, Rickard SE, Orcheson LJ, and Fong H: Antitumorigenic effect of a mammary lignan precursor from flaxseed. Nutr Cancer 26, 159-165, 1996.
10. Rickard SE, Yuan YV, Chen J, and Thompson LU: Dose effects of flaxseed and its lignan on N-methyl-N-nitrosourea-induced mammary tumorigenesis in rats. Nutr Cancer 35, 50-57, 1999.
11. Yan L, Yee JA, Li D, McGuire MH, and Thompson LU: Dietary flax-seed supplementation and experimental metastasis of melanoma cells in mice. Cancer Lett 124, 181-186, 1998.
12. Li D, Yee JA, Thompson LU, and Yan L: Dietary supplementation with secoisolariciresinol diglycoside (SDG) reduces experimental metastasis of melanoma cells in mice. Cancer Lett 142, 91-96, 1999.
13. Griffiths K, Morton MS, and Denis L: Certain aspects of molecular endocrinology that relate to the influence of dietary factors on the pathogenesis of prostate cancer. Eur Urol 35, 443-455, 1999.
14. Wang C, Makela T, Hase T, Adlercreutz H, and Kurzer MS: Lignans and flavonoids inhibit aromatase enzyme in human preadipocytes. J Steroid Biochem Mol Biol 50, 205-212, 1994.
15. Adlercreutz H, Bannwart C, Wahala K, Makela T, Brunow G, et al.: Inhibition of human aromatase by mammalian lignans and isoflavonoid phytoestrogens. J Steroid Biochem Mol Biol 44, 147-153, 1993.
16. Evans BA, Griffiths K, and Morton MS: Inhibition of 5α-reductase in genital skin fibroblasts and prostate tissue by dietary lignans and isoflavonoids. J Endocrinol 147, 295-302, 1995.
17. Kitts DD, Yuan YV, Wijewickreme AN, and Thompson LU: Antioxidant activity of the flaxseed lignan secoisolariciresinol diglycoside and its mammalian lignan metabolites enterodiol and enterolactone. Mol Cell Biochem 202, 91-100, 1999.
18. Prasad K: Antioxidant activity of secoisolariciresinol diglucoside-derived metabolites, secoisolariciresinol, enterodiol, and enterolactone. Int J Angiol 9, 220-225, 2000.
19. Hirano T, Fukuoka K, Oka K, and Matsumoto Y: Differential sensitivity of human gastric cancer ATPase and normal gastric mucosa ATPase to the synthetic mammalian lignan analogue 2,3-dibenzyl-butane-1,4-diol (hattalin). Cancer Invest 9, 145-150, 1991.
20. Hirano T, Fukuoka K, Oka K, Naito T, Hosaka K, et al.: Antiproliferative activity of mammalian lignan derivatives against the human breast carcinoma cell line, ZR-75-1. Cancer Invest 8, 595-602, 1990.
21. Fotsis T, Pepper M, Adlercreutz H, Fleischmann G, Hase T, et al.: Genistein, a dietary-derived inhibitor of in vitro angiogenesis. Proc Natl Acad Sci USA 90, 2690-2694, 1993.
22. Rickard SE, Yuan YV, and Thompson LU: Plasma insulin-like growth factor I levels in rats are reduced by dietary supplementation of flax-seed or its lignan secoisolariciresinol diglycoside. Cancer Lett 161, 47-55, 2000.
23. Canadian Council on Animal Care: Guide to the Care and Use of Experimental Animals. Ottawa, ON, Canada: Canadian Council on Animal Care, 1984.
24. Welch DR: Technical considerations for studying cancer metastasis in vivo. Clin Exp Metastasis 15, 272-306, 1997.
25. Armitage P: Tests for linear trends in proportions and frequencies. Biometrics 11, 375-386, 1955.
26. Nandi S, Guzman RC, and Yang J: Hormones and mammary carcinogenesis in mice, rats, and humans: a unifying hypothesis. Proc Natl Acad Sci USA 92, 3650-3657, 1995.
27. Akiyama T, Ishida J, Nakagawa S, Ogawara H, Watanabe S, et al.: Genistein, a specific inhibitor of tyrosine-specific protein kinases. J Biol Chem 262, 5592-5595, 1987.
28. Petit AM, Rak J, Hung MC, Rockwell P, Goldstein N, et al.: Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases downregulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151, 1523-1530, 1997.
29. Akagi Y, Liu W, Zebrowski B, Xie K, and Ellis LM: Regulation of vascular endothelial growth factor expression in human colon cancer by insulin-like growth factor-1. Cancer Res 58, 4008-4014, 1998.
30. Tischer E, Mitchell R, Hartman T, Silva M, Gospodarowicz D, et al.: The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J Biol Chem 266, 11947-11954, 1991.
31. Zhang HT, Scott PA, Morbidelli L, Peak S, Moore J, et al.: The 121 amino acid isoform of vascular endothelial growth factor is more strongly tumorigenic than other splice variants in vivo. Br J Cancer 83, 63-68, 2000.
32. Rose DP and Connolly JM: Regulation of tumor angiogenesis by dietary fatty acids and eicosanoids. Nutr Cancer 37, 119-127, 2000.
33. Rose DP, Connolly JM, Rayburn J, and Coleman M: Influence of diets containing eicosapentaenoic or docosahexaenoic acid on growth and metastasis of breast cancer in nude mice. JNCI 87, 587-592, 1995.
34. Liu X-H, Connolly JM, and Rose DP: Eicosanoids as mediators of linoleic acid-stimulated invasion and type IV collagenase production by a metastatic human breast cancer cell line. Clin Exp Metastasis 14, 145-152, 1996.
35. Natarajan R and Nadler J: Role of lipoxygenases in breast cancer. Front Biosci 8, E81-E88, 1998.
36. Clarke R, Thompson EW, Leonessa F, Lippman J, McGarvey M, et al.: Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res Treat 24, 227-239, 1993.
37. Chen J and Thompson LU: Lignans and tamoxifen, alone and in combination, inhibit the invasion and adhesion of metastatic human breast cancers in vitro (abstr). FASEB J 13, A582, 1999.